Stock Market & Financial Investment News

News Breaks December 14, 2012 08:07 EDT ARIA, MRK EMA says Merck withdraws application for Jenzyl The European Medicines Agency said on November 27 Merck Sharp & Dohme (MRK) officially notified the Committee for Medicinal Products for Human Use, or CHMP, that it wishes to withdraw its application for a marketing authorization for Jenzyl, for the maintenance treatment of patients with metastatic soft tissue sarcoma or bone sarcoma previously treated with chemotherapy. Jenzyl is the trade name for ridaforolimus, which is being co-developed by Merck and ARIAD Pharmaceuticals (ARIA). Jenzyl was expected to be used for the treatment of adults with soft tissue sarcoma, a type of cancer that affects the soft, supporting tissues of the body, or bone sarcoma that have spread to other parts of the body. The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated a list of questions. The company had not yet responded to the last round of questions at the time of the withdrawal. Based on the review of the data and the company’s response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Jenzyl could not have been approved for the treatment of patients with metastatic soft tissue sarcoma or bone sarcoma as maintenance therapy, the CHMP said. News For ARIA;MRK From The Last 14 Days Check below for free stories on ARIA;MRK the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 09:38 EDT MRK Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL AMAT FDX MA C GOOG DISH AMRN MRK BIDU June 18, 2013 16:00 EDT MRK Options Update; June 18, 2013 Subscribe for More Information 08:37 EDT MRK Drug companies turn to microchips to test medicines, WSJ reports Subscribe for More Information June 17, 2013 08:36 EDT MRK InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. June 14, 2013 17:15 EDT MRK Merck cutting layer of R&D management, WSJ reports Merck is planning to cut jobs and strip a level of senior management from its R&D unit, reports The Wall Street Journal. Reference Link 13:21 EDT MRK Merck to cut jobs, restructure R&D unit, Dow Jones reports June 12, 2013 16:02 EDT MRK Options Update; June 12, 2013 Subscribe for More Information 10:35 EDT MRK Merck management to meet with ISI Group Subscribe for More Information 08:04 EDT MRK Merck says independent review of JANUVIA safety profile 'welcomed' Subscribe for More Information June 11, 2013 08:01 EDT MRK Leerink's major pharma and biotech analysts hold a conference call Subscribe for More Information 07:42 EDT MRK Boston Biotech Conferences to host a conference Subscribe for More Information 07:41 EDT ARIA ARIAD initiates Phase 2 trial of Iclusig Subscribe for More Information 07:27 EDT ARIA William Blair to host a conference Subscribe for More Information June 10, 2013 11:41 EDT MRK Merck loss in Nasonex patent fight upheld on appeal Merck Sharp & Dohme, formerly known as Schering, appealed a lower court ruling in favor of Apotex. Reference Link June 7, 2013 08:17 EDT ARIA ARIAD has a conference call hosted by JPMorgan Subscribe for More Information June 6, 2013 16:01 EDT MRK Options Update; June 6, 2013 CBOE Volatility Index VIX down 72c to 16.78. Option volume leaders: AAPL TSLA GOOG C MRK BAC according to Track Data. Sign up for a free trial to see the rest of the stories you've been missing.